Palmitate Diet-induced Loss of Cardiac Caveolin-3: A Novel Mechanism for Lipid-induced Contractile Dysfunction

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Knowles, Catherine J ^a   Cebova, Martina ^a   Pinz, Ilka M ^a  

^a Maine Medical Center Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CAVEOLIN 3; CERAMIDE; MEDIUM CHAIN TRIACYLGLYCEROL; PALMITIC ACID; RYANODINE RECEPTOR; SATURATED FATTY ACID; SPHINGOMYELIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CARDIOVASCULAR RISK; CAVEOLA; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DISEASE ASSOCIATION; FAT INTAKE; FEMALE; HUMAN; HUMAN TISSUE; INTRACELLULAR SIGNALING; LIPID DIET; LIPID STORAGE; MALE; MOUSE; NONHUMAN; OBESITY; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SYSTOLIC CONTRACTILE DYSFUNCTION; SYSTOLIC DYSFUNCTION; TISSUE DISTRIBUTION; TRANSVERSE TUBULAR SYSTEM;

ANIMALS; CALCIUM; CARDIOMYOPATHIES; CAVEOLIN 3; CELL MEMBRANE; CERAMIDES; DIET, HIGH-FAT; FEMALE; GENE EXPRESSION; HEART; HUMANS; MALE; MICE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; OBESITY; PALMITIC ACID; PROTEIN ISOFORMS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SPHINGOMYELINS; TRIGLYCERIDES;

MUS;

EID: 84876035990     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061369     Document Type: Article

References (56)

1. Shankar SS, Steinberg HO, (2005) FFAs: do they play a role in vascular disease in the insulin resistance syndrome? Curr Diab Rep 5: 30-35.
2. Hallgren B, Stenhagen S, Svanborg A, Svennerholm L, (1960) Gas chromatographic analysis of the fatty acid composition of the plasma lipids in normal and diabetic subjects. J Clin Invest 39: 1424-1434 doi:10.1172/JCI104162.
3. Laakso M, Voutilainen E, Sarlund H, Aro A, Pyorala K, et al. (1985) Serum lipids and lipoproteins in middle-aged non-insulin-dependent diabetics. Atherosclerosis 56: 271-281.
4. Zuniga-Guajardo S, Zinman B, (1985) The metabolic response to the euglycemic insulin clamp in type I diabetes and normal humans. Metabolism 34: 926-930.
5. Campbell PJ, Carlson MG, Nurjhan N, (1994) Fat metabolism in human obesity. Am J Physiol 266: E600-E605.
6. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, et al. (2001) A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 107: 813-822.
7. Chiu HC, Kovacs A, Blanton RM, Han X, Courtois M, et al. (2005) Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 96: 225-233.
8. Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, et al. (2003) Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 111: 419-426.
9. Young ME, Guthrie PH, Razeghi P, Leighton B, Abbasi S, et al. (2002) Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes 51: 2587-2595.
10. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, et al. (2000) Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 97: 1784-1789.
11. Fauconnier J, Andersson DC, Zhang SJ, Lanner JT, Wibom R, et al. (2007) Effects of palmitate on Ca(2+) handling in adult control and ob/ob cardiomyocytes: impact of mitochondrial reactive oxygen species. Diabetes 56: 1136-1142.
12. Okere IC, (2006) Differential effects of saturated and unsaturated fatty acid diets on cardiomyocyte apoptosis, adipose distribution, and serum leptin. AJP: Heart and Circulatory Physiology 291: H38-H44.
13. Kong J, (2003) Mitochondrial effects with ceramide-induced cardiac apoptosis are different from those of palmitate. Archives of Biochemistry and Biophysics 412: 196-206.
14. Miller TA, LeBrasseur NK, Cote GM, Trucillo MP, Pimentel DR, et al. (2005) Oleate prevents palmitate-induced cytotoxic stress in cardiac myocytes. Biochemical and Biophysical Research Communications 336: 309-315.
15. Tsang M, (2004) Palmitate increases nitric oxide synthase activity that is involved in palmitate-induced cell death in cardiomyocytes. Nitric Oxide 10: 11-19.
16. Stan RV, (2005) Structure of caveolae. Biochim Biophys Acta 1746: 334-348.
17. Anderson RG, (1998) The caveolae membrane system. Annu Rev Biochem 67: 199-225.
18. Okamoto T, Schlegel A, Scherer PE, Lisanti MP, (1998) Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem 273: 5419-5422.
19. Bruns RR, Palade GE, (1968) Studies on blood capillaries. I. General organization of blood capillaries in muscle. J Cell Biol 37: 244-276.
20. Parton RG, Way M, Zorzi N, Stang E, (1997) Caveolin-3 associates with developing T-tubules during muscle differentiation. The Journal of Cell Biology 136: 137-154.
21. Biederer CH, (2000) The Basic Helix-Loop-Helix Transcription Factors Myogenin and Id2 Mediate Specific Induction of Caveolin-3 Gene Expression during Embryonic Development. Journal of Biological Chemistry 275: 26245-26251.
22. Galbiati F, Engelman JA, Volonte D, Zhang XL, Minetti C, et al. (2001) Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities. J Biol Chem 276: 21425-21433.
23. Smythe GM, (2003) A caveolin-3 mutant that causes limb girdle muscular dystrophy type 1C disrupts Src localization and activity and induces apoptosis in skeletal myotubes. Journal of Cell Science 116: 4739-4749.
24. Augustus AS, Buchanan J, Gutman E, Rengo G, Pestell RG, et al. (2008) Hearts lacking caveolin-1 develop hypertrophy with normal cardiac substrate metabolism. Cell Cycle 7: 2509-2518.
25. Woodman SE, Park DS, Cohen AW, Cheung MW-C, Chandra M, et al. (2002) Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J Biol Chem 277: 38988-38997.
26. Park DS, Woodman SE, Schubert W, Cohen AW, Frank PG, et al. (2002) Caveolin-1/3 double-knockout mice are viable, but lack both muscle and non-muscle caveolae, and develop a severe cardiomyopathic phenotype. Am J Pathol 160: 2207-2217.
27. Zhao Y-Y, Liu Y, Stan R-V, Fan L, Gu Y, et al. (2002) Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci USA 99: 11375-11380.
28. Vassilopoulos S, Oddoux S, Groh S, Cacheux M, Fauré J, et al. (2010) Caveolin 3 Is Associated with the Calcium Release Complex and Is Modified via in Vivo Triadin Modification. Biochemistry 49: 6130-6135.
29. Balijepalli RC, Foell JD, Hall DD, Hell JW, Kamp TJ, (2006) Localization of cardiac L-type Ca(2+) channels to a caveolar macromolecular signaling complex is required for beta(2)-adrenergic regulation. Proc Natl Acad Sci USA 103: 7500-7505.
30. Pinz I, Wax SD, Anderson P, Ingwall JS, (2008) Low over-expression of TNFalpha in the mouse heart increases contractile performance via TNFR1. J Cell Biochem 105: 99-107.
31. Pinz I, Zhu M, Mende U, Ingwall JS (2011) An Improved Isolation Procedure for Adult Mouse Cardiomyocytes. Cell Biochem Biophys.
32. Bielawski J, Szulc ZM, Hannun YA, Bielawska A, (2006) Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 39: 82-91.
33. Cremesti AE, Goni FM, Kolesnick R, (2002) Role of sphingomyelinase and ceramide in modulating rafts: do biophysical properties determine biologic outcome? FEBS Letters 531: 47-53.
34. Smith G, (2007) Matters of the heart: the physiology of cardiac function and failure. Experimental Physiology 92: 973-986.
35. Galbiati F, Engelman JA, Volonte D, Zhang XL, Minetti C, et al. (2001) Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities. J Biol Chem 276: 21425-21433.
36. Kim F, Pham M, Luttrell I, Bannerman DD, Tupper J, et al. (2007) Toll-Like Receptor-4 Mediates Vascular Inflammation and Insulin Resistance in Diet-Induced Obesity. Circulation Research 100: 1589-1596.
37. Lessard SJ, Rivas DA, Chen ZP, Bonen A, Febbraio MA, et al. (2007) Tissue-Specific Effects of Rosiglitazone and Exercise in the Treatment of Lipid-Induced Insulin Resistance. Diabetes 56: 1856-1864.
38. Parra V, Eisner V, Chiong M, Criollo A, Moraga F, et al. (2007) Changes in mitochondrial dynamics during ceramide-induced cardiomyocyte early apoptosis. Cardiovascular Research 77: 387-397.
39. Peterson JM, Wang Y, Bryner RW, Williamson DL, Alway SE, (2008) Bax signaling regulates palmitate-mediated apoptosis in C2C12 myotubes. Am J Physiol Endocrinol Metab 295: E1307-E1314.
40. Carrer DC, Schreier S, Patrito M, Maggio B, (2006) Effects of a Short-Chain Ceramide on Bilayer Domain Formation, Thickness, and Chain Mobililty: DMPC and Asymmetric Ceramide Mixtures. Biophysical Journal 90: 2394-2403.
41. Kong JY, Rabkin SW, (2004) Reduction of palmitate-induced cardiac apoptosis by fenofibrate. Mol Cell Biochem 258: 1-13.
42. Zhu H, Yang Y, Wang Y, Li J, Schiller PW, et al. (2011) MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1. Cardiovascular Research 92: 75-84.
43. Minetti C, Sotgia F, Bruno C, Scartezzini P, Broda P, et al. (1998) Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet 18: 365-368.
44. Hnasko R, Lisanti MP, (2003) The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. Mol Interv 3: 445-464.
45. Sotgia F, Woodman SE, Bonuccelli G, Capozza F, Minetti C, et al. (2003) Phenotypic behavior of caveolin-3 R26Q, a mutant associated with hyperCKemia, distal myopathy, and rippling muscle disease. Am J Physiol, Cell Physiol 285: C1150-C1160.
46. Woodman SE, Sotgia F, Galbiati F, Minetti C, Lisanti MP, (2004) Caveolinopathies: mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases. Neurology 62: 538-543.
47. Hayashi T, Arimura T, Ueda K, Shibata H, Hohda S, et al. (2004) Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy. Biochemical and Biophysical Research Communications 313: 178-184.
48. Rajab A, Straub V, McCann LJ, Seelow D, Varon R, et al. (2010) Fatal Cardiac Arrhythmia and Long-QT Syndrome in a New Form of Congenital Generalized Lipodystrophy with Muscle Rippling (CGL4) Due to PTRF-CAVIN Mutations. PLoS Genet 6: e1000874.
49. Cronk LB, Ye B, Kaku T, Tester DJ, Vatta M, et al. (2007) Novel mechanism for sudden infant death syndrome: persistent late sodium current secondary to mutations in caveolin-3. Heart Rhythm 4: 161-166.
50. Park DS, Woodman SE, Schubert W, Cohen AW, Frank PG, et al. (2002) Caveolin-1/3 double-knockout mice are viable, but lack both muscle and non-muscle caveolae, and develop a severe cardiomyopathic phenotype. Am J Pathol 160: 2207-2217.
51. Couchoux H, Bichraoui H, Chouabe C, Altafaj X, Bonvallet R, et al. (2011) Caveolin-3 is a direct molecular partner of the Cav1.1 subunit of the skeletal muscle L-type calcium channel. Int J Biochem Cell Biol 43: 713-720.
52. Lyon AR, MacLeod KT, Zhang Y, Garcia E, Kanda GK, et al. (2009) Loss of T-tubules and other changes to surface topography in ventricular myocytes from failing human and rat heart. Proc Natl Acad Sci USA 106: 6854-6859.
53. Louch W, (2004) Reduced synchrony of Ca2+ release with loss of T-tubules-a comparison to Ca2+ release in human failing cardiomyocytes. Cardiovascular Research 62: 63-73.
54. Nikolaev VO, Moshkov A, Lyon AR, Miragoli M, Novak P, et al. (2010) 2-Adrenergic Receptor Redistribution in Heart Failure Changes cAMP Compartmentation. Science 327: 1653-1657.
55. Wei S, Guo A, Chen B, Kutschke W, Xie YP, et al. (2010) T-Tubule Remodeling During Transition From Hypertrophy to Heart Failure. Circulation Research 107: 520-531.
56. Calaghan S, Kozera L, White E, (2008) Compartmentalisation of cAMP-dependent signalling by caveolae in the adult cardiac myocyte. Journal of Molecular and Cellular Cardiology 45: 88-92.